| Accession Number | 0001193125-26-382456 |
|---|---|
| Form Type | 4 |
| Filing Date | Sep 4, 2026 |
| Document | View SEC Filing |
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
President, Oncology | Common Stock | โ | Sep 1, 2026 | Grant/Award | 138 | $113.38 | $15,646.44 | 4,206 | Direct | โ | View Details | |
President, Oncology | Common Stock | โ | Sep 1, 2026 | Grant/Award | 138 | $0.00 | $0.00 | 4,344 | Direct | โ | View Details | |
President, Oncology | Common Stock | โ | Sep 2, 2026 | Tax Withholding | 102 | $113.38 | $11,564.76 | 4,242 | Direct | โ | View Details | |
President, Oncology | Common Stock | โ | Sep 2, 2026 | Exercise/Conversion | 58,333 | $21.63 | $1,261,742.79 | 62,575 | Direct | โ | View Details | |
President, Oncology | Common Stock | โ | Sep 2, 2026 | Sale | 23,600 | $109.35 | $2,580,674.16 | 38,975 | Direct | โ | View Details | |
President, Oncology | Common Stock | โ | Sep 2, 2026 | Sale | 23,770 | $110.70 | $2,631,348.51 | 15,205 | Direct | โ | View Details | |
President, Oncology | Common Stock | โ | Sep 2, 2026 | Sale | 1,537 | $111.37 | $171,180.76 | 13,668 | Direct | โ | View Details | |
President, Oncology | Common Stock | โ | Sep 2, 2026 | Sale | 974 | $112.40 | $109,474.29 | 12,694 | Direct | โ | View Details | |
President, Oncology | Common Stock | โ | Sep 2, 2026 | Sale | 1,606 | $113.72 | $182,632.23 | 11,088 | Direct | โ | View Details | |
President, Oncology | Common Stock | โ | Sep 2, 2026 | Sale | 5,621 | $114.58 | $644,042.38 | 5,467 | Direct | โ | View Details | |
President, Oncology | Common Stock | โ | Sep 2, 2026 | Sale | 1,225 | $115.44 | $141,413.39 | 4,242 | Direct | โ | View Details | |
President, Oncology | Stock option (right to buy) | Derivative | Sep 2, 2026 | Exercise/Conversion | 58,333 | $0.00 | $0.00 | 141,667 | Direct | โ | View Details |